Obesity, along with dyslipidemia and hyperglycemia, is a metabolic disorder growing in prevalence that is linked to chronic diseases such as atherosclerosis, hypertension, and type 2 diabetes. This study evaluated the anti-obesity, lipid-lowering, and anti-hyperglycemic effects of CB-02 capsules containing dry extracts of Phyllanthus emblica L., Dendrobium catenatum Lindl., and Gynostemma pentaphyllum in HFD-induced obese Swiss albino mice. After 12 weeks of HFD induction, mice were treated orally with CB-02 (576 or 1152 mg/kg/day) for 8 weeks. CB-02 significantly reduced BW gain, AC, the Lee obesity index, and the relative weights of visceral fat and major organs. It also improved lipid profiles by decreasing TC, TG, LDL-C, and non-HDL-C, while increasing HDL-C. These effects were comparable to orlistat (60 mg/kg/day). Furthermore, CB-02 lowered fasting glucose and improved insulin sensitivity, as indicated by an increased QUICKI and HOMA-β and reduced HOMA-IR. Histopathological evaluation showed that CB-02 reduced hepatic steatosis and inflammatory cell infiltration and also attenuated β-cell morphological alterations and pancreatic histopathological damage. These results suggest that CB-02 may be a promising therapeutic candidate for managing obesity and its comorbidities, including dyslipidemia, hyperglycemia, and hepatic steatosis, contributing to the prevention of type 2 diabetes and cardiovascular diseases in obese individuals.

Obesity, along with dyslipidemia and hyperglycemia, is a growing metabolic disorder linked to chronic diseases such as atherosclerosis, hypertension, and type 2 diabetes. This study evaluated the anti-obesity, lipid-lowering, and anti-hyperglycemic effects of CB-02 capsules containing dry extracts of Phyllanthus emblica L., Dendrobium officinale, and Gynostemma pentaphyllum in HFD-induced obese Swiss albino mice. After 12 weeks of HFD induction, mice were treated orally with CB-02 (576 or 1152 mg/kg/day) for 8 weeks. CB-02 significantly reduced BW gain, AC, Lee index, and the relative weights of visceral fat and major organs. It also improved lipid profiles by decreasing TC, TG, LDL-C, and non-HDL-C, while increasing HDL-C. These effects were comparable to orlistat (60 mg/kg/day). Furthermore, CB-02 lowered fasting glucose and improved insulin sensitivity, as indicated by an increased QUICKI and HOMA-β and reduced HOMA-IR. Histopathological evaluation showed that CB-02 reduced hepatic steatosis and inflammatory cell infiltration, as well as attenuated β-cell morphological alterations and pancreatic histopathological damage. These results suggest that CB-02 may be a promising therapeutic candidate for managing obesity and its comorbidities, including dyslipidemia, hyperglycemia, and hepatic steatosis, contributing to the prevention of type 2 diabetes and cardiovascular diseases in obese individuals.

Mục tiêu: Đánh giá độc tính liều lặp lại của viên nang NPB trong thời gian 90 ngày theo Hướng dẫn của Bộ Y tế và Tổ chức Hợp tác và Phát triển Kinh tế (OECD). Phương pháp nghiên cứu: Chuột uống mẫu thử NPB với liều 336 mg/kg/ngày và 1.680 mg/kg/ngày trong 90 ngày, đánh giá độc tính dựa vào cân nặng chuột, các xét nghiệm huyết học, sinh hóa máu và hình ảnh mô bệnh học. Kết quả: Sau 90 ngày được cho uống NPB, tình trạng chung, các chỉ số huyết học, các chỉ số sinh hóa máu đánh giá chức năng gan thận và mô bệnh học các tạng của chuột bình thường, không khác biệt so với lô chứng. Kết luận: Viên nang NPB liều 336 mg/kg/ngày và 1.680 mg/kg/ngày an toàn, không gây độc tính khi cho chuột cống trắng uống trong 90 ngày.